Drugs are developed for the ‘average patient’. Whilst this one-size-fits-all approach may make treatments suitable for some, they don’t provide the most effective fit for all.
Drugs are developed for the ‘average patient’. Whilst this one-size-fits-all approach may make treatments suitable for some, they don’t provide the most effective fit for all.
We need to change the way the human diseases are modelled to optimize the development of new drugs and advance personalized, precision medicine.
Our unique, innovative drug development platforms take into account variations in patients’ genetics, environments, and lifestyles that enable precision, carefully targeted drug development from the early stages of the process – resulting in safer and more cost-effective drug discovery.
What’s more, this innovative technology can prevent the needless loss of countless animal lives in a process that often fails to predict human responses accurately.
With a heavy reliance on immortal cell lines and animal studies, conventional research methodologies fail to stimulate the dynamics of drug-organ, drug-drug, and drug-organ-organ interactions.
Integrating tissue engineering and cellular technologies for the creation of organs on chips, our microphysiological modelling systems offer a ground-breaking opportunity to develop new tools for research and development, disease modelling, pharmacology, and toxicology, without the need for animal testing.
With a heavy reliance on immortal cell lines and animal studies, conventional research methodologies fail to stimulate the dynamics of drug-organ, drug-drug, and drug-organ-organ interactions.
Integrating tissue engineering and cellular technologies for the creation of organs on chips, our microphysiological modelling systems offer a ground-breaking opportunity to develop new tools for research and development, disease modelling, pharmacology, and toxicology, without the need for animal testing.
When it comes to drug discovery, one of the most significant challenges we face is identifying which drug candidates are likely to harm the liver, before they undergo human testing.
Precision during drug development is essential as drug metabolism enzymes, such as human cytochrome P450, are encoded by 50 or more genes with a range of polymorphism, resulting in either increased or decreased activity.
What’s more, due to the species-specific difference in liver pathways and limited physiologically relevant information from in vitro models, ‘silent’ hepatotoxic drugs are frequently introduced into clinical trials, leading to late-stage drug failure or post-marketing withdrawals.
Our innovative liver on-chip platform provides a practical solution – replicating the microarchitecture and functions of the human liver. These microchips are genuinely game-changing in the world of medicine and pharmaceuticals.
Stemnovate have been nominated in the the One to Watch category of the Cambridge Independent Science and Technology awards , it has been announced. For a full list on nominees and further details go HERE ...
08 October, 2018No comment
Cambridge Independent features Stemnovate in their latest article: It takes, on average, about 12 years for a new medicine to reach the market – and the typical cost is an eye-watering £1.2billion. Only one in 5,000 drugs ever makes it that far. Most of those......
09 November, 2018No comment